SGLT2 inhibitor alleviates hypomagnesemia in patients with chronic kidney disease: a retrospective observational study

被引：0
|
作者：
Osawa, Kosuke [1 ]
Ohya, Masaki [2 ]
Yamamoto, Shuto [2 ]
Nakashima, Yuri [2 ]
Tanaka, Yusuke [2 ]
Yamano, Yukiko [2 ]
Takatsuka, Taisuke [2 ]
Araki, Shin-Ichi [2 ]
机构：
[1] Wakayama Med Univ, Dept Nephrol, Wakayama, Japan
[2] Wakayama Med Univ, Sch Med, Dept Nephrol, Wakayama, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.1220
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
646
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
    Mende, Christian W.
    ADVANCES IN THERAPY, 2022, 39 (01) : 148 - 164
  • [42] Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease
    Mark, Patrick B.
    Sattar, Naveed
    LANCET, 2022, 400 (10365): : 1745 - 1747
  • [43] SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
    Sloan, Lance
    POSTGRADUATE MEDICINE, 2024, 136 (08) : 801 - 809
  • [44] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    David C. Wheeler
    June James
    Dipesh Patel
    Adie Viljoen
    Amar Ali
    Marc Evans
    Kevin Fernando
    Debbie Hicks
    Nicola Milne
    Philip Newland-Jones
    John Wilding
    Diabetes Therapy, 2020, 11 : 2757 - 2774
  • [45] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    Wheeler, David C.
    James, June
    Patel, Dipesh
    Viljoen, Adie
    Ali, Amar
    Evans, Marc
    Fernando, Kevin
    Hicks, Debbie
    Milne, Nicola
    Newland-Jones, Philip
    Wilding, John
    DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
  • [46] Comment on "The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease"
    Chen, I. -Wen
    Chang, Li-Chen
    Hung, Kuo-Chuan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (06) : 2115 - 2116
  • [47] Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
    Ahluwalia, Tarunveer S.
    Ronkko, Teemu K. E.
    Eickhoff, Mie K.
    Curovic, Viktor Rotbain
    Siwy, Justyna
    Eder, Susanne
    Denicolo, Sara
    Mayer, Gert
    Mischak, Harald
    Rossing, Peter
    Persson, Frederik
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (02): : 334 - 346
  • [48] Comment on “The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease”
    I.-Wen Chen
    Li-Chen Chang
    Kuo-Chuan Hung
    International Urology and Nephrology, 2024, 56 : 2115 - 2116
  • [49] Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
    Li, Ning
    Lv, Dan
    Zhu, Xiangjun
    Wei, Ping
    Gui, Yuan
    Liu, Shijia
    Zhou, Enchao
    Zheng, Min
    Zhou, Dong
    Zhang, Lu
    FRONTIERS IN MEDICINE, 2021, 8
  • [50] Effect of SGLT2 Inhibitor Therapy on Urinary Podocyte Markers in Diabetic Kidney Disease
    Li Chuanlei
    Szeto, Cheuk-Chun
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
12345